Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma

被引:16
|
作者
Hillengass, Jens [1 ]
Zechmann, Christian M. [2 ]
Nadler, Andreas [1 ]
Hose, Dirk
Cremer, Friedrich W. [3 ]
Jauch, Anna [3 ]
Heiss, Christiane [4 ,5 ]
Benner, Axel [4 ]
Ho, Anthony D. [1 ]
Bartram, Claus R.
Kauczor, Hans-Ulrich [2 ]
Delorme, Stefan [2 ]
Goldschmidt, Hartmut [1 ,5 ]
Moehler, Thomas M. [1 ]
机构
[1] Univ Heidelberg, Dept Hematol Oncol & Rheumatol, D-69120 Heidelberg, Germany
[2] German Canc Res Ctr, Dept Radiol, D-6900 Heidelberg, Germany
[3] Univ Heidelberg, Inst Human Genet, D-69120 Heidelberg, Germany
[4] German Canc Res Ctr, Dept Biostat, D-6900 Heidelberg, Germany
[5] Natl Ctr Tumor Dis, Sect Multiple Myeloma, Heidelberg, Germany
关键词
multiple myeloma; monoclonal gammopathy of undetermined significance; dynamic contrast-enhanced magnetic resonance imaging; cytogenetics; in situ fluorescence hybridization;
D O I
10.1002/ijc.23455
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To identify genetic mechanisms controlling bone marrow microcirculation and angiogenesis in patients with plasma cell disease we simultaneously performed bone marrow dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and cytogenetics (iFISH) on CD138 purified plasma cells of MGUS (n = 31) and untreated multiple myeloma (MM) (n = 87) patients. The adverse cytogenetic abnormalities gain of 1q21, deletion 17p13 and deletion 13q14 significantly correlated with at least one DCE-MRI finding (aberrant "focal" microcirculation pattern, increase in median microcirculation parameter Amplitude A or exchange rate constant kep). We conclude that gain of 1q21, deletion 13q14 and deletion 17p13 trigger the angiogenic cascade in MM. Our findings will have important implications for the design, analysis and stratification for clinical studies of patients with MM in particular if compounds with antiangiogenic activity are used. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:2871 / 2875
页数:5
相关论文
共 50 条
  • [21] Prognostic value of 1q21 amplification in multiple myeloma
    Abramova, T. V.
    Obukhova, T. N.
    Mendeleev, L. P.
    Pokrovskaya, O. S.
    Gribanova, E. O.
    Ryzhko, V. V.
    Grebenyuk, L. A.
    Nareyko, M. V.
    Solovyev, M. V.
    Votyakova, O. M.
    Kulikov, S. M.
    Rusinov, M. A.
    Savchenko, V. G.
    TERAPEVTICHESKII ARKHIV, 2017, 89 (07) : 32 - +
  • [22] Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis
    Wang, Yu-Tong
    Bao, Li
    Chu, Bin
    Chen, Xiao-Huan
    Lu, Min-Qiu
    Shi, Lei
    Gao, Shan
    Fang, Li-Juan
    Xiang, Qiu-Qing
    Ding, Yue-Hua
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2022, 36 (07)
  • [23] The prognostic role of 1q21 gain/amp in newly diagnosed multiple myeloma: the faster, the worse
    Wang, Yawen
    Xu, Jiadai
    Liu, Peng
    Li, Panpan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S160 - S160
  • [24] Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies
    Bisht, Kamlesh
    Walker, Brian
    Kumar, Shaji K.
    Spicka, Ivan
    Moreau, Philippe
    Martin, Tom
    Costa, Luciano J.
    Richter, Joshua
    Fukao, Taro
    Mace, Sandrine
    van de Velde, Helgi
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (12) : 1099 - 1114
  • [25] Amplification of 1q21 and Other Abnormalities in Multiple Myeloma Patients from a Tertiary Hospital in Singapore
    Lim, Alvin S. T.
    Krishnan, Sathish
    Lim, Tse Hui
    See, Karen
    Ng, Yit Jun
    Tan, Yu Min
    Choo, Natasha
    Lau, Lai Ching
    Tien, Sim Leng
    Ma, Jun
    Tan, Daryl
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2014, 30 (04) : 253 - 258
  • [26] Amplification of 1q21 and Other Abnormalities in Multiple Myeloma Patients from a Tertiary Hospital in Singapore
    Alvin S. T. Lim
    Sathish Krishnan
    Tse Hui Lim
    Karen See
    Yit Jun Ng
    Yu Min Tan
    Natasha Choo
    Lai Ching Lau
    Sim Leng Tien
    Jun Ma
    Daryl Tan
    Indian Journal of Hematology and Blood Transfusion, 2014, 30 : 253 - 258
  • [27] The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse
    Wang, Yawen
    Xu, Jiadai
    Xu, Bei
    Li, Panpan
    Yang, Yang
    Wang, Wenjing
    Xu, Tianhong
    Maihemaiti, Aziguli
    Lan, Tianwei
    Wang, Pu
    Ren, Liang
    Zhou, Chi
    Aihemaiti, Xianmuseye
    Liu, Peng
    CANCER, 2023, 129 (07) : 1005 - 1016
  • [28] Gain of chromosome 1q21: Pathogenesis, prognostication, and treatment of a time-lapsed multiple myeloma
    Hose, D.
    Seckinger, A.
    Meissner, T.
    Hielscher, T.
    Reme, T.
    Moreaux, J.
    Bertsch, U.
    Hillengass, J.
    Jauch, A.
    Goldschmidt, H.
    Neben, K.
    ONKOLOGIE, 2013, 36 : 40 - 41
  • [29] Clinical and biological characteristics of multiple myeloma with 1q21 amplification
    钟仕贞
    China Medical Abstracts(Internal Medicine), 2016, 33 (02) : 52 - 52
  • [30] Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens
    Liu, Xiao
    Jia, Shuangshuang
    Chu, Yuping
    Tian, Biao
    Gao, Yaya
    Zhang, Chunyan
    Zheng, Yanhua
    Jia, Weijing
    Liu, Xiangxiang
    Yuan, Ruifeng
    Zhang, Na
    Feng, Juan
    Dong, Hongjuan
    Xin, Xiaoli
    Cao, Zhengcong
    Tang, Hailong
    Chang, Ziwei
    Gao, Guangxun
    FRONTIERS IN ONCOLOGY, 2022, 12